Results of a Phase III trial with Alpharadin (radium 223-chloride) were presented at the European Cancer Organization and Congress of the European Society for Medical Oncology (ECCO-ESMO) conference in Stockholm this year. Treatment with Alpharadin was associated with a 30% reduction of dying during follow up. The patients with advanced metastatic disease in the bone increased average survival (median) from 11.2 months to 14 months. The trial ended prematurely because of the good results.
Chris Parker, M.D. of the Royal Marsden Hospital in London was interviewed by Pieter Droppert from Biotech Strategy Blog.